Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ainos, Inc. - warrants
(NQ:
AIMDW
)
0.0579
UNCHANGED
Delayed Quote
Updated: 10:56 AM EDT, Oct 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ainos, Inc. - warrants
< Previous
1
2
3
4
5
6
Next >
Ainos Regains Compliance with Nasdaq Minimum Bid Price Requirement
January 02, 2024
Via
ACCESSWIRE
Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-development Powered by AI Nose, Accelerating the Digitalization of Smell
December 26, 2023
Via
ACCESSWIRE
Ainos, Inc. Announces Stock Consolidation
December 12, 2023
Via
ACCESSWIRE
Ainos Announces Successful Manufacturing of VELDONA GMP Clinical Batch by Swiss Pharmaceutical
November 28, 2023
Via
ACCESSWIRE
Ainos Announces Positive Data Reported from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA
November 21, 2023
Via
ACCESSWIRE
Ainos Reports Third Quarter 2023 Financial Results
November 09, 2023
Via
ACCESSWIRE
Ainos Announces Placement of Initial $3 Million Tranche of $10 Million Private Placement
September 25, 2023
Via
ACCESSWIRE
Ainos Commences Shipping its VELDONA Pet Cytoprotein Supplements in Taiwan
September 05, 2023
Via
ACCESSWIRE
Ainos Reports Second Quarter 2023 Financial Results
August 11, 2023
Via
ACCESSWIRE
Ainos’ VELDONA Granted Orphan Drug Designation by U.S. FDA for Potential Treatment of Oral Warts in HIV-Seropositive Patients
September 18, 2023
Via
ACCESSWIRE
Ainos Celebrates First Listing Anniversary on Nasdaq
August 10, 2023
Via
ACCESSWIRE
Ainos Partners with Nisshinbo Micro Devices and Inabata to Co-Develop VOC Sensing Platform For Broader Industry Adoption
August 09, 2023
Via
ACCESSWIRE
Ainos Issues Mid-Year Business Update Letter to Shareholders
June 27, 2023
Via
ACCESSWIRE
Ainos Provides Insights Into Its AI Nose Technology
June 20, 2023
Via
ACCESSWIRE
Ainos Completes VELDONA Pet Line-Up by Launching New VELDONA Pet Shiny and Slim in Push Towards $20M Revenue Target
June 14, 2023
Via
ACCESSWIRE
Ainos Launches New VELDONA Pet Lohas and Soothing Health Supplements, Catalyzing Its Drive to $20M Sales Target
June 07, 2023
Via
ACCESSWIRE
Ainos Launches VELDONA Pet Cytoprotein Health Supplement Targeting $20M in Sales
May 30, 2023
Via
ACCESSWIRE
Ainos Appoints Amanda Sung as New Chief Financial Officer
May 17, 2023
Via
ACCESSWIRE
Ainos Reports First Quarter 2023 Financial Results
May 12, 2023
Via
ACCESSWIRE
Ainos Reports Fourth Quarter and Full Year 2022 Financial Results
March 31, 2023
Via
ACCESSWIRE
Ainos Signs Agreement Establishing Topmed as Exclusive Distributor of VELDONA Animal Health Supplements in Taiwan
March 21, 2023
Via
ACCESSWIRE
Ainos and Merdury Sign MoU to Explore Phase 3 Study of VELDONA Drug Candidate for Treatment of Oral Warts in HIV-Seropositive Patients
March 14, 2023
Via
ACCESSWIRE
Ainos Announces US$3 Million Convertible Notes Private Placement
March 13, 2023
Via
ACCESSWIRE
Ainos and Tah-An Sign MoU to Explore Manufacture of VELDONA Animal Investigational New Drug
January 23, 2023
Via
ACCESSWIRE
Ainos Issues 2023 Shareholder Letter
January 17, 2023
Via
ACCESSWIRE
Ainos Pursues Licensing Partners to Accelerate Five Candidates of its Low-dose Oral Interferon Formulation VELDONA to Phase 3 Trials and Commercialization
October 31, 2022
Via
ACCESSWIRE
Ainos Announces Positive Results from Additional Preclinical Study of Its Low-dose Oral Interferon Formulation Against New Variant Virus - Omicron
September 30, 2022
Via
ACCESSWIRE
Ainos Submits Investigational New Drug Application to the U.S. FDA to Conduct Phase 2 Trial of its VELDONA Low-dose Oral Interferon Formulation Against Mild COVID-19 Symptoms
August 24, 2022
Via
ACCESSWIRE
Ainos Announces Master Services Agreement with Swiss Pharmaceutical, Ltd. for Drug Testing, Manufacturing, and Packaging for its VELDONA Product Candidates
August 17, 2022
Via
ACCESSWIRE
Ainos Reports Second Quarter 2022 Financial Results
August 15, 2022
Via
ACCESSWIRE
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
